Literature DB >> 24576478

Involvement of cholesterol in hepatitis B virus X protein-induced abnormal lipid metabolism of hepatoma cells via up-regulating miR-205-targeted ACSL4.

Ming Cui1, Zelin Xiao1, Baodi Sun1, Yue Wang2, Minying Zheng1, Lihong Ye2, Xiaodong Zhang3.   

Abstract

Hepatitis B virus X protein (HBx) plays crucial roles in the development of hepatocellular carcinoma (HCC). The abnormal lipid metabolism is involved in the hepatocarcinogenesis. We previously reported that HBx suppressed miR-205 in hepatoma cells. In this study, we supposed that HBx-decreased miR-205 might contribute to the abnormal lipid metabolism according to the bioinformatics analysis. Interestingly, we showed that the expression levels of acyl-CoA synthetase long-chain family member 4 (ACSL4) were negatively associated with those of miR-205 in clinical HCC tissues. Then, we validated that miR-205 was able to inhibit the expression of ACSL4 at the levels of mRNA and protein through targeting its 3'UTR. Strikingly, we found that HBx was able to increase the levels of cellular cholesterol, a metabolite of ACSL4, in hepatoma cells, which could be blocked by miR-205 (or Triacsin C, an inhibitor of ACSL4). However, anti-miR-205 could increase the levels of cholesterol in the cells. Moreover, we demonstrated that the levels of cholesterol were increased in the liver of HBx transgenic mice in a time course manner. Functionally, oil red O staining revealed that HBx promoted lipogenesis in HepG2 cells, which could be abolished by miR-205 (or Triacsin C). However, anti-miR-205 was able to accelerate lipogenesis in the cells. Interestingly, the treatment with Triacsin C could remarkably block the role of anti-miR-205 in the event. Thus, we conclude that miR-205 is able to target ACSL4 mRNA. The HBx-depressed miR-205 is responsible for the abnormal lipid metabolism through accumulating cholesterol in hepatoma cells.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ACSL4; Abnormal lipid metabolism; Choleterol; HBx; Hepatocellular carcinoma; miR-205

Mesh:

Substances:

Year:  2014        PMID: 24576478     DOI: 10.1016/j.bbrc.2014.02.068

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  25 in total

1.  Long non-coding RNA LINC00673 promotes hepatocellular carcinoma progression and metastasis through negatively regulating miR-205.

Authors:  Li-Guo Zhang; Xin-Ke Zhou; Ru-Jian Zhou; Hui-Zeng Lv; Wei-Peng Li
Journal:  Am J Cancer Res       Date:  2017-12-01       Impact factor: 6.166

Review 2.  Non-coding RNAs in ferroptotic cancer cell death pathway: meet the new masters.

Authors:  Mehdi Rabiee Valashedi; Chia Bamshad; Nima Najafi-Ghalehlou; Amirsadegh Nikoo; Kazuo Tomita; Yoshikazu Kuwahara; Tomoaki Sato; Amaneh Mohammadi Roushandeh; Mehryar Habibi Roudkenar
Journal:  Hum Cell       Date:  2022-04-12       Impact factor: 4.174

Review 3.  Regulatory pathways and drugs associated with ferroptosis in tumors.

Authors:  Dan Wang; Le Tang; Yijie Zhang; Guili Ge; Xianjie Jiang; Yongzhen Mo; Pan Wu; Xiangying Deng; Lvyuan Li; Sicheng Zuo; Qijia Yan; Shanshan Zhang; Fuyan Wang; Lei Shi; Xiayu Li; Bo Xiang; Ming Zhou; Qianjin Liao; Can Guo; Zhaoyang Zeng; Wei Xiong; Zhaojian Gong
Journal:  Cell Death Dis       Date:  2022-06-10       Impact factor: 9.685

Review 4.  MicroRNAs and Noncoding RNAs in Hepatic Lipid and Lipoprotein Metabolism: Potential Therapeutic Targets of Metabolic Disorders.

Authors:  Neetu Sud; Jennifer Taher; Qiaozhu Su
Journal:  Drug Dev Res       Date:  2015-08-19       Impact factor: 4.360

5.  MiR-506 suppresses proliferation of hepatoma cells through targeting YAP mRNA 3'UTR.

Authors:  Yue Wang; Ming Cui; Bao-di Sun; Fa-bao Liu; Xiao-dong Zhang; Li-hong Ye
Journal:  Acta Pharmacol Sin       Date:  2014-08-04       Impact factor: 6.150

Review 6.  Fatty acid activation in carcinogenesis and cancer development: Essential roles of long-chain acyl-CoA synthetases.

Authors:  Yue Tang; Jing Zhou; Shing Chuan Hooi; Yue-Ming Jiang; Guo-Dong Lu
Journal:  Oncol Lett       Date:  2018-05-30       Impact factor: 2.967

Review 7.  microRNAs as pharmacogenomic biomarkers for drug efficacy and drug safety assessment.

Authors:  Igor Koturbash; William H Tolleson; Lei Guo; Dianke Yu; Si Chen; Huixiao Hong; William Mattes; Baitang Ning
Journal:  Biomark Med       Date:  2015-10-26       Impact factor: 2.851

Review 8.  The impact of hepatitis B virus x protein and microRNAs in hepatocellular carcinoma: a comprehensive analysis.

Authors:  Li Lin; Xiaomao Yin; Xiumei Hu; Qian Wang; Lei Zheng
Journal:  Tumour Biol       Date:  2014-10-07

9.  MicroRNA‑205 promotes the tumorigenesis of nasopharyngeal carcinoma through targeting tumor protein p53-inducible nuclear protein 1.

Authors:  Guohui Nie; Hongfang Duan; Xiaoqing Li; Zhendong Yu; Liang Luo; Ruijing Lu; Ziliang Ji; Wei Zhang
Journal:  Mol Med Rep       Date:  2015-08-05       Impact factor: 2.952

10.  Serum microRNA 143 and microRNA 215 as potential biomarkers for the diagnosis of chronic hepatitis and hepatocellular carcinoma.

Authors:  Zhu-qing Zhang; Hua Meng; Nan Wang; Li-na Liang; Li-na Liu; Shu-ming Lu; Yong Luan
Journal:  Diagn Pathol       Date:  2014-07-02       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.